Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NYSE BHVN traded up $2.05 during midday trading on Friday, reaching $47.03. 695,349 shares of the company traded hands, compared to its average volume of 733,267. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $29.17 and a 52 week high of $67.86. The stock has a 50-day moving average price of $40.27 and a 200 day moving average price of $49.71. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -7.65 and a beta of 0.32.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.26). As a group, equities analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -7.51 earnings per share for the current fiscal year.
A number of research firms have issued reports on BHVN. Morgan Stanley set a $50.00 target price on Biohaven Pharmaceutical and gave the company a “hold” rating in a research note on Friday, August 9th. Zacks Investment Research cut Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Cantor Fitzgerald set a $87.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. Canaccord Genuity set a $80.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 26th. Finally, Goldman Sachs Group set a $89.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $69.36.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Featured Story: What is a support level?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.